Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Capital Expenditures (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Capital Expenditures data on record, last reported at $600000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 2900.0% year-over-year to $600000.0; the TTM value through Dec 2025 reached $954000.0, down 3.93%, while the annual FY2025 figure was $954000.0, 3.93% down from the prior year.
  • Capital Expenditures reached $600000.0 in Q4 2025 per MIRM's latest filing, up from $187000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $779000.0 in Q2 2024 and bottomed at $3000.0 in Q1 2021.
  • Average Capital Expenditures over 5 years is $147375.0, with a median of $41000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: tumbled 96.94% in 2021, then soared 7966.67% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $3000.0 in 2021, then skyrocketed by 7966.67% to $242000.0 in 2022, then tumbled by 71.9% to $68000.0 in 2023, then crashed by 70.59% to $20000.0 in 2024, then skyrocketed by 2900.0% to $600000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $600000.0 in Q4 2025, $187000.0 in Q3 2025, and $126000.0 in Q2 2025.